New Cholesteryl Ester Transfer Protein from Indonesian Herbal Plants as Candidate Treatment of Cardiovascular Disease


  • Ratih Dewi Yudhani Department of Pharmacology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia; Biomedical Laboratory, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
  • Khariz Fahrurrozi Undergraduate Student, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
  • Dono Indarto Biomedical Laboratory, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia; Department of Physiology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia



Cardiovascular disease, Cholesterol ester transfer protein inhibitor, Molecular docking, Indonesian plants, Phytochemical screening, In silico


BACKGROUND: There is a strong negative relationship between high-density lipoprotein cholesterol (HDL-C) and the risk of cardiovascular disease (CVD). Cholesterol ester transfer protein (CETP) is a glycoprotein transporter that transfers cholesterol esters to very low-density lipoprotein and low-density lipoprotein cholesterol (LDL-C). The CETP inhibitor is a new strategy against CVD because of its ability to increase HDL-C. Various Indonesian plants have not been optimally used, and in silico phytochemical screening of these plants showing potential as CETP inhibitors is still limited.

AIM: This study for exploring Indonesian phytochemicals as CETP inhibitors for new CVD treatments.

METHODS: We screened 457 phytochemicals registered in the herbal database and met Lipinski’s rule of five. Their molecular structures were downloaded from the PubChem database. The three-dimensional structures of CETP and dalcetrapib (the CETP inhibitor standard) were obtained from a protein data bank ( with the 4EWS code and ZINC database with the ZINC03976476 code, respectively. CETP–dalcetrapib binding complexes were validated 5 times using AutoDock Vina 1.1.2 software. Interactions between CETP and phytochemicals were molecularly docked with the same software and visualized using Pymol 1.8× software.

RESULTS: Dalcetrapib had a docking score of −9.22 kcal/mol and bound to CETP at Ser230 and His232 residues. The 11 phytochemicals had lower binding scores than dalcetrapib, but only L-(+)-tartaric acid, chitranone, and oxoxylopine could interact with CETP at the Ser230 residue. These are commonly found in Tamarindus indica, Plumbago zeylanica, and Annona reticulata, respectively.

CONCLUSION: L-(+)-Tartaric acid, chitranone, and oxoxylopine show potential as CETP inhibitors in silico.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Li Z, Lin L, Wu H, Yan L, Wang H, Yang H, et al. Global, regional, and national death, and Disability-Adjusted Life-Years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the global burden of disease study and implications for prevention. Front Public Health. 2021;9:559751. PMid:34778156 DOI:

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1999-2019. Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. PMid:33309175 DOI:

Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth Extend study. PLosOne. 2019;14(4):e0215219. PMid:31039155 DOI:

Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. CETP inhibition: Past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37-42. PMid:26997876 DOI:

Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323-31. PMid:22661899 DOI:

Farrer S. Beyond statins: Emerging evidence for HDL-increasing therapies and diet in treating cardiovascular disease. Adv Prev Med. 2018;2018:6024747. PMid:30112217

Chirasani VR, Senapati S. How cholesteryl ester transfer protein can also be a potential triglyceride transporter. Sci Rep. 2017;7(1):6159. PMid:28733595 DOI:

Woudberg NJ, Pedretti S, Lecour S, Schulz R, Vuilleumier N, James RW, et al. Pharmacological intervention to modulate HDL: What do we target? Front Pharmacol. 2018;8:989. PMid:29403378 DOI:

Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a new CETP inhibitor: The new tool for the management of dyslipidemias? Diseases. 2017;5(4):21. PMid:28961179 DOI:

Rifaioglu AS, Atas H, Martin MJ, Atalay RC, Atalay V, Doğan T. Recent applications of deep learning and machine intelligence on in silico drug discovery: Methods, tools and databases. Brief Bioinform. 2019;20(5)1878-912. PMid:30084866 DOI:

Banchi L, Fingerhuth M, Babej T, Ing C, Arrazola JM. Molecular docking with Gaussian Boson sampling. Sci Adv. 2020;6(23):eaax1950. PMid:32548251 DOI:

Liu S, Mistry A, Reynolds JM, Lloyd DB, Griffor MC, Perry DA, et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. JBC. 2012;287(44):37321-9. PMid:22961980 DOI:

Shrestha S, Wu BJ, Guiney L, Barter PJ, Rey KA. Cholesteryl ester transfer protein and its inhibitors. J Lipid Res. 2018;59(5):772-83. PMid:29487091 DOI:

Nicholls SJ, Bubb K. The mystery of evacetrapib-why are CETP inhibitors failing? Expert Rev Cardiovasc Ther. 2020;18(3):127-30. PMid:32200670 DOI:

Boyd NK, Teng C, Frei CR. Brief overview of approaches and challenges in new antibiotic development: A focus on drug repurposing. Front Cell Infect Microbiol. 2021;11:684515. PMid:34079770 DOI:

Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203-7. PMid:10910363 DOI:

Pinzi L, Rastelli G. Molecular docking: Shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331. PMid:31487867 DOI:

Ta’rraga WA, Garda HA, Toledo JD, Gonzalez MC. Potential inhibitors of the activity of the cholesterol-ester transfer protein. J Comput Biol. 2019;26(12):1458-69. PMid:31356116 DOI:

Ranaletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51(9):2739-52. PMid:20458119 DOI:

Ferreira L, Dos Santos R, Oliva G, Andricopulo A. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384-421. PMid:26205061 DOI:

Khalaf RA, Sabbah D, Al-Shalabi E, Bishtawi S, Albadawi G, Sheika GA. Synthesis, biological evaluation, and molecular modeling study of substituted benzyl benzamides as CETP inhibitors. Arch Pharm (Weinheim). 2017;350(12):e1700204. PMid:29112287 DOI:

Khalaf RA, Al-Rawashdeh S, Sabbah D, Sheikha GA. Molecular docking and pharmacophore modelling studies of fluorinated benzamides as potential CETP inhibitors. Med Chem. 2017;13(3):239-53. PMid:27823564 DOI:

Zhang M, Lei D, Peng B, Yang M, Zhang L, Charles MA, et al. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors. Biochim Biophys Acta Mol Cell Biol. 2017;1862(12):1606-17. PMid:28911944 DOI:

Arshad MS, Imran M, Ahmad A, Sohaib M. Ullah A, Nisa MU, et al. Tamarind: A diet-based strategy against lifestyle maladies. Food Sci Technol. 2019;7(11):3378-90. PMid:31762991 DOI:

Salamah NN, Aryati WD, Yanuar A. Virtual screening of Indonesian herbal database as adenosine A2A antagonist using AutoDock and AutoDock Vina. Pharmacogn J. 2019;11(6):1219-24. DOI:

Nugraha AS, Damayanti YD, Wangchuk P, Keller PA. Anti-infective and anti-cancer properties of the Annona species: Their ethnomedicinal uses, alkaloid diversity, and pharmacological activities. Molecules. 2019;24(23):4419. PMid:31816948 DOI:

Aprilia CA, Ninditasari G, Walujo D. Hypolipidemic effect and antioxidant activity of tamarind leaves extract in hypercholesterol-fed rats. Indonesian J Cardiol. 2017;38(2):72-80. DOI:

Lim CY, Junit SM, Aziz AA, Jayapalan JJ, Hashim OH. The hypolipidemic effects of Tamarindus indica fruit pulp extract in normal and diet-induced hypercholesterolemic hamsters are associated with altered levels of serum proteins. Electrophoresis. 2018;39(23):2965-73. PMid:30280388 DOI:

Uchenna UE, Shori AB, Baba AS. Tamarindus indica seeds improve carbohydrate and lipid metabolism: An in vivo study. J Ayurveda Integr Med. 2018;9(4):258-65. PMid:29203351 DOI:

Asgary S, Soltani R, Barzegar N, Sarrafzadegan N. Evaluation on the effects of Tamarindus Indica L. fruit on body weight and several cardiometabolic risk factors in obese and overweight adult patients: A randomized controlled clinical trial. Int J Prev Med. 2020;11:24. PMid:32175064

Pai SA, Munshi RP, Pancal FH, Gaur IS, Mestry SN, Gursahani MS, et al. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress. Biomed Pharmacother. 2019;111(2019):686-94. PMid:30611993 DOI:

Sasso S, Souza PC, Santana LF, Cardaso CA, Alves FM, Portugal LC, et al. Use of an extract of Annona muricata Linn to prevent high-fat diet induced metabolic disorders in C57BL/6 mice. Nutrients. 2019;11(7):1509. PMid:3126972 DOI:




How to Cite

Yudhani RD, Fahrurrozi K, Indarto D. New Cholesteryl Ester Transfer Protein from Indonesian Herbal Plants as Candidate Treatment of Cardiovascular Disease. Open Access Maced J Med Sci [Internet]. 2022 Nov. 17 [cited 2024 May 21];10(A):1624-9. Available from:

Most read articles by the same author(s)